Ulcerative Colitis (UC) Clinical Trial
Official title:
Utility of Narrow Band Endoscopy in Predicting Short and Long Term Risk of Relapse in Patients With Quiescent Ulcerative Colitis
Ulcerative colitis (UC) is a chronic inflammatory condition of unknown aetiology,
characterized by a diffuse confluent mucosal inflammation of the colon starting from the
rectum with a relapsing and remitting course. Conventional endoscopy was thought to be a
reliable parameter of disease activity, but microscopic inflammation can persist despite
normal mucosal findings. Histologically detectable inflammation is associated with a greater
risk of subsequent relapse. A flare in UC activity is difficult to predict, but a simple,
easily measured biological marker of relapse would be important in guiding the most
appropriate therapy.
Recent technological advances in fiber optics, light sources, detectors, and molecular
biology have stimulated development of numerous optical methods that promise to
significantly improve our ability to evaluate human epithelium in vivo. These methods,
collectively termed "optical biopsy," are nondestructive in situ assays of mucosal
histopathology using light that can provide instantaneous tissue assessment. Narrow band
imaging (NBI) is a novel technique that enhances the diagnostic capability of endoscopes in
characterising tissues by using filters in a redgreenblue (RGB) sequential illumination
system. This results in improved mucosal contrast and detail.
UC always involves the distal colon and activity is usually greatest in rectosigmoid area.
This makes evaluation of the rectum and sigmoid an attractive marker in patients with UC.
Unlike serum and faecal markers, endoscopic assessment of the mucosa is unlikely to be
affected by systemic disease and would be acceptable test for patients and physicians.
We plan to evaluate THE rectosigmoid mucosa in patients with UC by flexible endoscope using
both white light and NBI endoscopy. These patients will be followed by for one year or until
they relapse, whichever comes first. The aim of our study is to develop endoscopic
biomarkers to predict relapse in acute and quiescent UC.
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02819635 -
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05960864 -
Chinese Spondyloarthritis Inception Cohort (CESPIC)
|
||
| Not yet recruiting |
NCT05316220 -
A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis
|
Phase 3 | |
| Completed |
NCT02345733 -
Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis
|
Phase 4 | |
| Terminated |
NCT02217722 -
Use of the Ulcerative Colitis Diet for Induction of Remission
|
N/A | |
| Completed |
NCT02778464 -
Faecal Calprotectin as a Potential Non-invasive Inflammatory Marker in Pregnancy and Inflammatory Bowel Disease
|
||
| Completed |
NCT01971814 -
Early Serum Infliximab Levels in Severe Ulcerative Colitis.
|
Phase 1 | |
| Completed |
NCT03223012 -
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
|
||
| Active, not recruiting |
NCT03456206 -
Chronic Inflammatory Disease, Lifestyle and Risk of Disease
|
||
| Completed |
NCT04254783 -
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
|
Phase 1 | |
| Completed |
NCT03398148 -
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT02087878 -
A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma
|
||
| Completed |
NCT02065622 -
Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis
|
Phase 3 | |
| Completed |
NCT03695185 -
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy
|
Phase 2 | |
| Completed |
NCT02108821 -
Fecal Microbiota Transplantation in Pediatric Patients
|
Phase 1 | |
| Terminated |
NCT03758443 -
Efficacy & Safety of TD-1473 in Ulcerative Colitis
|
Phase 2/Phase 3 | |
| Completed |
NCT01364896 -
Anal Human Papillomavirus in Inflammatory Bowel Disease Study
|
||
| Terminated |
NCT03920254 -
TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study
|
Phase 2/Phase 3 | |
| Recruiting |
NCT01277419 -
German Spondyloarthritis Inception Cohort
|
||
| Recruiting |
NCT05377580 -
A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis
|
Phase 2 |